XML 28 R2.htm IDEA: XBRL DOCUMENT v3.24.2.u1Close
Condensed Consolidated Statements of Income (Unaudited) - USD ($)
shares in Thousands, $ in Millions
3 Months Ended 6 Months Ended
Jun. 30, 2024
Jun. 30, 2023
Jun. 30, 2024
Jun. 30, 2023
Total revenue $ 2,464.9 $ 2,456.0 $ 4,755.4 $ 4,919.0 Close
Cost and expenses:        
Cost of sales, excluding amortization and impairment of acquired intangible assets 546.0 592.7 1,088.2 1,255.5
Research and development 513.9 584.2 966.8 1,154.8
Selling, general and administrative 553.8 548.0 1,135.3 1,153.0
Amortization and impairment of acquired intangible assets 86.9 52.9 165.2 103.1
Collaboration profit sharing/(loss reimbursement) 62.4 56.9 128.0 114.0
Restructuring charges 6.6 34.4 18.1 44.0
Gain on sale of priority review voucher, net 88.6 0.0 88.6 0.0
Other (income) expense, net 85.2 (121.2) 178.9 (51.8)
Total cost and expense 1,766.2 1,747.9 3,591.9 3,772.6 Close
Income before income tax (benefit) expense 698.7 708.1 1,163.5 1,146.4 Close
Income tax (benefit) expense 115.1 114.8 186.5 165.5 Close
Net income 583.6 593.3 977.0 980.9 Close
Net income (loss) attributable to noncontrolling interests, net of tax 0.0 1.7 0.0 1.4
Net income attributable to Biogen Inc. $ 583.6 $ 591.6 $ 977.0 $ 979.5
Net income per share:        
Basic earnings per share attributable to Biogen Inc. $ 4.01 $ 4.09 $ 6.72 $ 6.78
Diluted earnings per share attributable to Biogen Inc. $ 4.00 $ 4.07 $ 6.70 $ 6.74
Weighted-average shares used in calculating:        
Basic earnings per share attributable to Biogen Inc. 145,600 144,700 145,400 144,600
Diluted earnings per share attributable to Biogen Inc. 145,900 145,500 145,900 145,400
Product, net        
Total revenue $ 1,899.6 $ 1,845.8 $ 3,611.5 $ 3,609.1
Revenue from anti-CD20 therapeutic programs        
Total revenue 444.5 433.4 838.5 832.9
Contract manufacturing, royalty and other revenue        
Total revenue $ 120.8 $ 176.8 $ 305.4 $ 477.0